Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Ther Drug Monit. 2013 Dec;35(6):796-802. doi: 10.1097/FTD.0b013e3182959080.

Development and validation of a high-performance liquid chromatography ultraviolet method for lapatinib quantification in human plasma.

Author information

  • 1*Platform of Oncology, Hospital Quirón, Torrevieja (Alicante); and †Pharmacokinetics and Drug Metabolism Department, AMGEN Inc, Valencia, Spain.


A selective and precise high-performance liquid chromatography ultraviolet method was developed and validated for the determination of lapatinib in human plasma. After protein precipitation with acetonitrile, lapatinib and sorafenib were separated using isocratic elution (on a C18 Ultrabase column using a mobile phase of acetonitrile/20 mM ammonium acetate in a proportion 53:47 (v/v) pumped at a constant flow rate of 1.2 mL/min). Quantification was performed at 260 nm. Calibration curves were linear over the range 0.2-10 µg/mL. Inter- and intraday coefficients of variation were less than 7%. The limit of detection and the lower limit of quantification were 0.1 and 0.2 µg/mL, respectively. Recoveries of lapatinib from plasma were higher than 86.7% in all cases. The assay was applied to the determination of the drug in the plasma of 2 cancer patients receiving lapatinib, 1000 and 1250 mg orally, and could be useful for therapeutic drug monitoring of lapatinib in routine clinical practice.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk